Gilead Sciences | Nettoeinkommen

Aktienkurs
154.98
Täglich Wechseln
3.17 2.09%
Monatlich
24.91%
Jährlich
48.90%
Q1 Prognose
147.82




Nettoeinkommen Veränderung Datum
AbbVie USD 1.82B 1.63B 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
ALKERMES USD 82.76M 4.34M 2025-09
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Biogen USD 466.5M 168.3M 2025-09
BioMarin Pharmaceutical USD -30.74M 271.28M 2025-09
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Coherus Biosciences USD -56.57M 5.87M 2025-03
Eli Lilly USD 6.64B 1.05B 2025-12
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
Glaxosmithkline GBP 2.71B 1.27B 2025-09
Incyte USD 299.28M 124.89M 2025-12
J&J USD 5.12B 36M 2025-12
Merck USD 2.96B 2.82B 2025-12
Moderna USD -200M 625M 2025-09
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 3.93B 96M 2025-09
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD 15.9M 80.75M 2025-09
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR -801M 3.6B 2025-12
Sarepta Therapeutics USD -179.95M 376.84M 2025-09
United Therapeutics USD 338.7M 29.2M 2025-09
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12


Gilead Sciences Nettoeinkommen - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.